Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 354

Results For "EU"

6107 News Found

Lupin receives tentative approval from USFDA for Selexipag for injection
Drug Approval | November 04, 2023

Lupin receives tentative approval from USFDA for Selexipag for injection

This product will be manufactured at Lupin's Nagpur facility in India

Zydus acquires UK based LiqMeds Group
News | November 02, 2023

Zydus acquires UK based LiqMeds Group

Zydus will pay an upfront consideration of GBP 68 million and yearly earn-outs until 2026

Aster DM Healthcare launches a 506-bed multi-specialty hospital in Bengaluru
Healthcare | November 02, 2023

Aster DM Healthcare launches a 506-bed multi-specialty hospital in Bengaluru

Aster Whitefield will be Aster's 3 rd multi-specialty hospital in Bengaluru and overall 19th hospital in India

Pfizer posts Q3 loss as Covid-19 revenues shrink
News | November 01, 2023

Pfizer posts Q3 loss as Covid-19 revenues shrink

Revenue in the three months ended on Oct. 1 also slipped by 42% to US$ 13.23 billion

Aragen setting up a US$ 30 million bio-manufacturing site in Bengaluru
Biotech | October 31, 2023

Aragen setting up a US$ 30 million bio-manufacturing site in Bengaluru

Biologics manufacturing to expand the Aragen platform by offering “gene to GMP” solution

Sun Pharma to co-market Zydus’s CKD treatment drug ‘Desidustat’ in India
News | October 31, 2023

Sun Pharma to co-market Zydus’s CKD treatment drug ‘Desidustat’ in India

The drug will be marketed by Sun Pharma under the brand name RYTSTAT

EnginZyme produces key mRNA vaccine ingredient using biocatalysis
Biotech | October 30, 2023

EnginZyme produces key mRNA vaccine ingredient using biocatalysis

2023 Nobel laureates discovered how pseudouridine could make mRNA suitable for vaccines

SN Bioscience announces Phase 1 study results of SN-38 nanoparticle anti-cancer drug
Clinical Trials | October 30, 2023

SN Bioscience announces Phase 1 study results of SN-38 nanoparticle anti-cancer drug

Impressive safety and efficacy for solid cancer patients followed by global clinical study plan

Dr Reddy's Q2 FY24 PAT jumps 33% to Rs 1,480 Cr
News | October 30, 2023

Dr Reddy's Q2 FY24 PAT jumps 33% to Rs 1,480 Cr

Dr Reddy’s Laboratories recorded revenue of Rs 6,880.20 crore during the quarter

Venus Remedies earns REO Certification from CII for second consecutive year
News | October 26, 2023

Venus Remedies earns REO Certification from CII for second consecutive year

The Responsible Export Organisation (REO) certification is a distinguished recognition awarded by the Confederation of Indian Industry (CII)

Latest Stories

Glycomine completes enrollment in Phase 2b trial for rare genetic disorder

Zeto gains FDA nod for new outpatient EEG system promising faster brain health testing

Beacon raises $132M+ to bring AI-driven sleep diagnostics to masses

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
Only 4-5 Indian pharma companies have a strong presence in Russia, opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Only 4-5 Indian pharma companies have a strong presence in Russia, opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Only 4-5 Indian pharma companies have a strong presence in Russia but the opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Only 4-5 Indian pharma companies have a strong presence in Russia but the opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Companies must shift from L1 costing to Life Cycle Cost Analysis: Abhilash Pasham, Associate GM - Central Engineering & Projects, Dr. Reddy's Laboratories
Companies must shift from L1 costing to Life Cycle Cost Analysis: Abhilash Pasham, Associate GM - Central Engineering & Projects, Dr. Reddy's Laboratories

Packaging